What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?

2.

Hultcrantz

M

,

Björkholm

M

,

Dickman

PW

, et al.

Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study

.

Ann Intern Med

.

2018

;

168

(

5

):

317

-

325

.

3.

Panova-Noeva

M

,

Marchetti

M

,

Russo

L

, et al.

ADP-induced platelet aggregation and thrombin generation are increased in essential thrombocythemia and polycythemia vera

.

Thromb Res

.

2013

;

132

(

1

):

88

-

93

.

4.

De Stefano

V

,

Za

T

,

Rossi

E

, et al;

GIMEMA CMD-Working Party

.

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

.

Haematologica

.

2008

;

93

(

3

):

372

-

380

.

5.

Barbui

T

,

Finazzi

G

,

Falanga

A

.

Myeloproliferative neoplasms and thrombosis

.

Blood

.

2013

;

122

(

13

):

2176

-

2184

.

6.

Gerds

AT

,

Mesa

R

,

Burke

JM

, et al.

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL

.

Blood

.

2024

;

143

(

16

):

1646

-

1655

.

7.

Carobbio

A

,

Ferrari

A

,

Masciulli

A

,

Ghirardi

A

,

Barosi

G

,

Barbui

T

.

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis

.

Blood Adv

.

2019

;

3

(

11

):

1729

-

1737

.

8.

Moliterno

AR

,

Kaizer

H

,

Reeves

BN

.

JAK2 V617F allele burden in polycythemia vera: burden of proof

.

Blood

.

2023

;

141

(

16

):

1934

-

1942

.

9.

De Stefano

V

,

Ruggeri

M

,

Cervantes

F

, et al.

High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists

.

Leukemia

.

2016

;

30

(

10

):

2032

-

2038

.

10.

Hernández-Boluda

J-C

,

Arellano-Rodrigo

E

,

Cervantes

F

, et al;

Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)

.

Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia

.

Ann Hematol

.

2015

;

94

(

6

):

911

-

918

.

11.

Wang

T-F

,

Khorana

A-A

,

Agnelli

G

, et al.

Treatment of cancer-associated thrombosis: recent advances, unmet needs, and future direction

.

Oncologist

.

2023

;

28

(

7

):

555

-

564

.

12.

Hamulyák

EN

,

Daams

JG

,

Leebeek

FWG

, et al.

A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms

.

Blood Adv

.

2021

;

5

(

1

):

113

-

121

.

13.

Huenerbein

K

,

Sadjadian

P

,

Becker

T

, et al.

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms

.

Ann Hematol

.

2021

;

100

(

8

):

2015

-

2022

.

14.

Fedorov

K

,

Goel

S

,

Kushnir

M

,

Billett

HH

.

Thrombosis in myeloproliferative neoplasms: treatment outcomes of direct oral anticoagulants and vitamin K antagonists

.

Res Pract Thromb Haemost

.

2021

;

5

(

6

):

e12574

.

15.

Landolfi

R

,

Marchioli

R

,

Kutti

J

, et al;

European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators

.

Efficacy and safety of low-dose aspirin in polycythemia vera

.

N Engl J Med

.

2004

;

350

(

2

):

114

-

124

.

16.

De Stefano

V

,

Finazzi

G

,

Barbui

T

.

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms

.

Blood Cancer J

.

2018

;

8

(

7

):

65

.

17.

Marchioli

R

,

Finazzi

G

,

Specchia

G

,

Masciulli

A

,

Mennitto

MR

,

Barbui

T

.

The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera

.

Thrombosis

.

2011

;

2011

:

794240

.

18.

Barbui

T

,

De Stefano

V

,

Ghirardi

A

,

Masciulli

A

,

Finazzi

G

,

Vannucchi

AM

.

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in polycythemia vera

.

Blood Cancer J

.

2018

;

8

(

12

):

124

.

19.

Vannucchi

AM

,

Kiladjian

JJ

,

Griesshammer

M

, et al.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera

.

N Engl J Med

.

2015

;

372

(

5

):

426

-

435

.

20.

Harrison

CN

,

Nangalia

J

,

Boucher

R

, et al.

Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial

.

J Clin Oncol

.

2023

;

41

(

19

):

3534

-

3544

.

21.

Gisslinger

H

,

Klade

C

,

Georgiev

P

, et al;

PROUD-PV Study Group

.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

.

Lancet Haematol

.

2020

;

7

(

3

):

e196

-

e208

.